Voriconazole-Clindamycin as First-Line Treatment for Suspected Pulmonary Aspergillosis in Tursiops Truncatus
IAAAM 2009
Natalia Deveaux1; Edgar Delgado2; Juan Bolaños2; María López2; Raúl Torres2
1Facultad de Medicina Veterinaria y Zootecnia. Circuito Exterior, Ciudad Universitaria, Del. Coyoacán, México; 2Grupo Via Delphi. Chetumal- Pto. Juárez, Interior del Parque Xcaret, Mpio. Solidaridad, Quintana Roo, México


Pulmonary aspergillosis is one of the most commonly reported mycotic diseases in marine mammals, and Aspergillus fumigatus has been isolated from most of the reported cases in bottlenose dolphins (Tursiops truncatus). The purpose of these case studies is to determine and establish an effective therapeutic option for pulmonary aspergillosis in bottlenose dolphins. Two cases of suspected pulmonary aspergillosis in bottlenose dolphins were observed at Delphinus Xcaret in Riviera Maya, Mexico. Both were 3-yr-old females presenting with anorexia, cough, tachypnea and an increased white blood cell count. The diagnosis of aspergillosis was based on serological tests. Treatment with voriconazole (V-fend®) and clindamycin (Dalacin C®) was initiated. The initial dose of voriconazole was 2.2 mg/kg BID for two days. The maintenance dose, given for four months, was 1.7 mg/kg BID. Clindamycin was administered at a dose of 9.25 mg/kg/day. The dolphins increased their food intake and both showed clinical improvement by decreasing the coughing and normalizing the total white blood cell count. Voriconazole-clindamycin seems to be an effective therapy for suspected pulmonary aspergillosis. The level of toxicity is low and there may be a complementary effect between antimycotic and antibiotic activities of both drugs.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Natalia Deveaux
Facultad de Medicina Veterinaria y Zootecnia
Circuito Exterior, Ciudad Universitaria
Del. Coyoacán, México

MAIN : Poster : Voriconazole-Clindamycin
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.


777 W. Covell Blvd., Davis, CA 95616



  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357